Stock Screener App

무료 -

설치하다

2.82

3.09% -0.09

시장 영업 전: 2.81 -0.010 -0.35%

Perspective Therapeutics Inc (CATX)

개요 뉴스 가격 이력 토론 예측 주식 분할

Perspective Therapeutics Inc 주식(CATX)의 최신 뉴스

Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [²¹²Pb]VMT-α-NET in GEP-NETs - Quiver Quantitative

CATX|Perspective Therapeutics Inc|Price:2.820|Chg%:-0.090 - TradingKey

Perspective Therapeutics Inc (CATX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Perspective Therapeutics Inc (CATX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Perspective Therapeutics Inc (CATX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Perspective Therapeutics Market Sentiment - Benzinga España

CATX|Perspective Therapeutics Inc|Price:2.910|Chg%:-0.045 - TradingKey

Perspective Therapeutics Inc (CATX) Cash Flow - TradingKey

Perspective Therapeutics Inc (CATX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Perspective Therapeutics Inc - TradingKey

Perspective Therapeutics, Inc. Revenue Breakdown – TRADEGATE:AAJ0 - TradingView

BTIG reiterates Perspective Therapeutics stock rating on manufacturing edge - Investing.com

Perspective Therapeutics Inc (CATX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Perspective Therapeutics Dips 0.67% as Stock Hovers Near Support ZoneFair Value Gap - dars.gov.et

Perspective Therapeutics (CATX) gains 5.3% beneficial holder led by Millennium - Stock Titan

Perspective Therapeutics (CATX) Bank of America Global Healthcare Conference 2026 summary - Quartr

Perspective Therapeutics (CATX) RBC Capital Markets Global Healthcare Conference 2026 summary - Quartr

Perspective Therapeutics (CATX) Morgan Stanley 22nd Annual Global Healthcare Conference summary - Quartr

Perspective Therapeutics to present updated can... - Pluang

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026 - The Manila Times

Perspective Therapeutics Announces ESMO 2026 Presentation of Updated [212Pb]VMT-α-NET Data in Advanced Neuroendocrine Tumors - Quiver Quantitative

Perspective's cancer-treatment data gets ESMO oral presentation Oct. 23 - Stock Titan

Is Perspective Therapeutics, Inc. (CATX) stock outpacing its medical peers this year? - MSN

Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Perspective Therapeutics (CATX) Slides Over 5% as Support Levels Come into FocusOutside Reversal - dars.gov.et

CATX: Key Management Meeting Insights from BTIG Analyst - GuruFocus

symbol__ Stock Quote Price and Forecast - CNN

Perspective Therapeutics, Inc. Announces Executive Changes - marketscreener.com

Perspective Therapeutics Names Paul Lyne Chief Science Officer as Co-Founder Michael Schultz Moves to Advisory Role - marketscreener.com

Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor - The Manila Times

Perspective Therapeutics (CATX) Barclays 27th Annual Global Healthcare Conference summary - Quartr

Perspective Therapeutics (CATX) 2024 Cantor Fitzgerald Global Healthcare Conference summary - Quartr

Perspective Therapeutics (CATX) Q4 2025 earnings summary - Quartr

Perspective Therapeutics (CATX) Proxy filing Summary - Quartr

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Tenaya Therapeutics (TNYA) - The Globe and Mail

Perspective Therapeutics (CATX) UBS Global Healthcare Conference Summary - Quartr

CATX Q1 2026 Earnings: Narrower Loss Beats Expectations as Pipeline Progress ContinuesRevenue Growth Report - dars.gov.et

Piper Sandler Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $16 - Moomoo

Perspective Therapeutics Expands Radiopharmaceutical Pipeline to Target Brain Tumors - sekbernews.id

Perspective Therapeutics (CATX) Reports Encouraging Early Data Across Multiple Radiopharmaceutical Trials - Yahoo Finance

Perspective Therapeutics (CATX) Surges 4.9% as Bullish Momentum Tests Key ResistanceBPI Bull Confirmed - DonanımHaber

Perspective Therapeutics Advances Next-Generation 212Pb Radiopharmaceuticals for Solid Tumor Treatment and Melanoma - Minichart

Perspective Therapeutics Highlights Progress in Alpha Radiopharmaceutical Pipeline - TipRanks

Perspective Therapeutics (CATX) updates radiopharmaceutical oncology pipeline presentation - Stock Titan

Millennium reports 4.89M shares (4.3%) in Perspective Therapeutics | CATX SEC FilingForm SCHEDULE 13G - Stock Titan

CATX: Analyst Engages with Management in Virtual Discussion - GuruFocus

Perspective Therapeutics, Inc. Actuals & Estimates (AMEX:CATX) - TradingView

Perspective Therapeutics, Inc. Actuals & Estimates (TRADEGATE:AAJ0) - TradingView

Enterprise value to revenue forward of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView

Price to earnings forward of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView

CATX Forecast — Price Target — Prediction for 2027 - TradingView

Price to book forward of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView

Perspective Therapeutics Inc (CATX) Institutional Confidence - TradingKey

Perspective Therapeutics Inc (CATX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Perspective Therapeutics Inc (CATX) Valuation: PE, PB & Fair Value Analysis - TradingKey

Perspective Therapeutics Inc. (CATX) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock Gain - dars.gov.et

ZBH

$92.07

0.79%

STE

$218.40

2.02%

PHG

$25.02

4.39%

GEHC

$61.12

0.89%

DXCM

$73.37

2.56%

EW

$83.04

0.50%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기 | MarketWatch에서 열기 | 로이터에서 공개